Company Profile - Minerva Neurosciences Inc

Introduction

Minerva Neurosciences Inc (Minerva Neurosciences) is a clinical-stage biopharmaceutical company that develops and commercializes a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The company's product candidates include MIN-101, a compound used for the treatment of patients with schizophrenia and MIN-117, a compound used for the treatment of patients suffering from major depressive disorder (MDD). It develops MIN-202, a selective orexin two (2) receptor antagonist used for the treatment of primary and secondary insomnia and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein used for the treatment of Parkinson's disease. The company has an operational presence in the US and Switzerland. Minerva Neurosciences is headquartered in Burlington, Massachusetts, the US